Prolactinoma is a condition in which a usually noncancerous tumor (adenoma) in the pituitary gland in your brain overproduces prolactin hormone. The main effect of prolactin is a decrease in the levels of some hormones — estrogen in women and testosterone in men.
Although Prolactinoma is not life-threatening, can impair your vision, cause infertility and produce other effects. Prolactinoma is one of several types of cancer that can develop in your pituitary gland.
Doctors may treat Prolactinoma with medications often effectively to restore your prolactin level to normal. Surgery to remove the pituitary tumor, may also be an option for treating Prolactinoma.
References Prolactinoma. National Institute of diabetes and digestive and kidney diseases. http://endocrine.niddk.nih.gov/pubs/prolact/prolact.htm. Accessed on 17 January 2011., Melmed S, et al., diagnosis and treatment of hyperprolactinemia: clinical practice guideline of An Endocrine Society. The Journal of Clinical Endocrinology Metabolism &. 2011; 273.96: Colao, et al., the aggressive pituitary tumour therapy. Pharmacotherapy specialist opinion. 2011; 12: 1561. Mann WA. Treatment of prolactinomas and hyperprolactinaemia: a lifetime approach. European Journal of Clinical Investigation. 2011; 334.41: a. Klibanski Prolactinomas. The New England Journal of Medicine. 2010; 352: 121. Colao, et al. medical treatment of prolactinomas. Nature reviews Endocrinology. 2011; 7: 267.var shareUrl = encodeURIComponent (window.location); var shareTitle = encodeURIComponent (document.title);Privacy Policy (updated August 2, 2011) terms and conditions of use policy (updated August 2, 2011)
LEGAL CONDITIONS AND TERMS OF USE APPLICABLE TO ALL USERS OF THIS SITE. ANY USE OF THIS SITE CONSTITUTES ACCEPTANCE OF THESE TERMS AND CONDITIONS OF USE.
© 1998-2012 Mayo Foundation for medical education and research.

The Ritchie Centre, Monash Institute of Medical Research, Monash University, Melbourne, AustraliaReceived 9 December 2011. Revised 20 April 2012. Accepted 20 April 2012. Available online 29 May 2012.View full text Sleep disordered breathing (SDB) is a common disorder in both adults and children and is caused by the obstruction of the upper airway during sleep. Unlike adults, most cases of paediatric SDB are due to the presence of enlarged tonsils and adenoids, thus the main treatment option is adenotonsillectomy (T&A). It is well known that obstructive sleep apnoea in adults increases the risk for hypertension, coronary artery disease and stroke, and there is now mounting evidence that SDB also has a significant impact on the cardiovascular system in children with reports of elevated blood pressure, endothelial dysfunction and altered autonomic cardiovascular control. As there is now substantial evidence that elevated blood pressure in childhood is carried on to adulthood it is important to know if treatment of SDB improves cardiovascular outcomes. Studies in adults have shown that treatment of SDB leads to improvements in cardiovascular function, including a reduction in pulmonary artery pressure, systemic blood pressure and endothelial dysfunction. However, studies exploring the outcomes of treatment of SDB in children on the cardiovascular system are limited and varied in their methodology and outcome measures. As a number of cardiovascular disturbances are sequelae of SDB, early detection and management could result in the reduction of elevated blood pressure in children, and consequently a reduction in cardiovascular morbidity in adulthood. The aim of this review is to summarise the findings of studies to date which have investigated the cardiovascular outcomes in children treated for SDB and to make recommendations for future management of this very common disease.prs.rt("abs_end");Adenotonsillectomy; Blood pressure; Cardiovascular; Children; Hypoxaemia; Inflammation; Obstructive sleep apnoea; Sleep disordered breathing; Treatment
